Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 15/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327054 | 0.92 | P2RY12 (0.56) | P2RY12ALDH1A1KDM4EL3MBTL1LMNA | |
| SCHEMBL3328020 | 0.90 | P2RY12 (0.57) | P2RY12ALDH1A1KDM4EL3MBTL1LMNA | |
| SCHEMBL3221673 | 0.88 | P2RY12 (0.69) | P2RY12KDM4ECYP3A4CYP2C9 | |
| SCHEMBL3328353 | 0.87 | P2RY12 (0.50) | P2RY12ALDH1A1KDM4EL3MBTL1LMNA | |
| SCHEMBL3584927 | 0.86 | P2RY12 (0.51) | P2RY12ALDH1A1KDM4EL3MBTL1LMNA | |
| SCHEMBL4740960 | 0.86 | P2RY12 (0.57) | P2RY12ALDH1A1KDM4EL3MBTL1LMNA | |
| SCHEMBL4872829 | 0.84 | P2RY12 (0.55) | P2RY12ALDH1A1KDM4EL3MBTL1LMNA | |
| SCHEMBL3585012 | 0.84 | P2RY12 (0.55) | P2RY12ALDH1A1KDM4EL3MBTL1LMNA | |
| SCHEMBL3328347 | 0.84 | L3MBTL1 (0.56) | P2RY12ALDH1A1KDM4EL3MBTL1LMNA | |
| SCHEMBL4871507 | 0.84 | P2RY12 (0.55) | P2RY12ALDH1A1KDM4EL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137277-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| EP-2111400-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | AstraZeneca AB (SE) | 2009-10-28 | — | — | EP | disclosed |
| US-20080171732-A1 | New Pyridine Analogues IX 519 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008085117-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171732-A1 | New Pyridine Analogues IX 519 | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885ALDH1A1 1518/4885KDM4E 3186/4885 |
| US-20100137277-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885ALDH1A1 1782/4885KDM4E 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.